The Austin, Texas–based company said Wednesday that FDA has cleared an Aries assay for group B streptococcus. It’s the third assay FDA has cleared for use with Luminex’s Aries systems.
The GBS assay has also received a CE-IVD marking. Luminex plans to launch additional Aries assays this year. Aries systems are meant to increase laboratory efficiency and ensure result accuracy.